Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD – Free Report) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.
A number of other research firms have also recently issued reports on PODD. Citigroup lifted their price target on Insulet from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Sanford C. Bernstein increased their price objective on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Canaccord Genuity Group lowered their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Finally, Benchmark reduced their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $185.67.
Get Our Latest Stock Analysis on Insulet
Insulet Stock Up 2.3%
NASDAQ PODD opened at $149.81 on Friday. The firm has a market cap of $10.39 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 1.25 and a beta of 1.06. Insulet has a one year low of $126.40 and a one year high of $354.88. The stock’s 50 day simple moving average is $142.06 and its 200 day simple moving average is $175.98. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83.
Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 EPS. As a group, sell-side analysts forecast that Insulet will post 6.75 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Insulet
Several hedge funds have recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC lifted its position in Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares during the period. Activest Wealth Management boosted its stake in shares of Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. WPG Advisers LLC grew its position in shares of Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares during the period. State of Wyoming grew its position in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares during the period. Finally, Continuum Advisory LLC acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $46,000.
About Insulet
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.
Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Insulet serves customers in the United States and international markets.
Featured Articles
- Five stocks we like better than Insulet
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
